The bioactivity of recombinant mSCF was determined in an M-07e cell proliferation assay. The ED50 of each lot is between 2-8 ng/ml.
Molecular Formula
Recombinant mSCF contains no "tags" and the nonglycosylated protein has a calculated MW of 18,298. DTT-reduced and non-reduced protein migrate as 22-35 kDa polypeptides. Lower mobility and heterogeneity in SDS-PAGE are due to glycosylation. The expected amino-terminal KEICG of recombinant mSCF was verified by amino acid sequencing.
Source
Human 293 Cells
Background
SCF is produced by endothelial cells, fibroblasts, keratinocytes, gut epithelial cells, and tumor cells. SCF is critical for hematopoiesis and mast cell differentiation and has additional roles in survival and function of other cell types. Some tumor cell proliferation and invasiveness are promoted by SCF. Tumor-derived SCF appears to be involved in expansion of myeloid-derived suppressor cells which, in turn, limits proliferation of tumor-infiltrating T-cells. SCF may have additional roles in the tumor microenvironment. SCF is either soluble or an integral membrane protein and its form is dependant on variation in splicing or proteolytic release. SCF binds to the receptor tyrosine kinase c-Kit and induces activation of the Akt, Erk, JNK, and p38 pathways.
References
[1] Broudy, V.C. (1997) Blood 90, 1345-64.
[2] Huang, B. et al. (2008) Blood 112, 1269-79.
[3] Yasuda, A. et al. (2006) Mol Cancer 5, 46.
[4] Pan, P.Y. et al. (2008) Blood 111, 219-28.
[5] Samayawardhena, L.A. and Pallen, C.J. (2008) J Biol Chem 283, 29175-85.
[6] Huang, H.M. et al. (2000) Blood 96, 1764-71.
